Promising clinical trial data have highlighted advances in the treatment of mantle cell lymphoma (MCL), but an important next step is applying this progress to routine clinical practice, said Andre Goy, MD.
These recent data have not only suggested that patients with MCL can expect a better quality of life with novel therapies, but also that maintenance regimens and chimeric antigen receptor (CAR) T-cell therapy could be a pivotal part of the future landscape.
For example, rituximab (Rituxan) has demonstrated activity in the maintenance setting. A meta-analysis presented at the 2018 ASCO Annual Meeting indicated that rituximab maintenance following induction chemoimmunotherapy significantly improved overall survival (OS) and progression-free survival (PFS) for patients with MCL.1
Read more: https://www.onclive.com/web-exclusives/goy-discusses-maintenance-car-tcell-therapy-in-mcl